OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
September 18, 2023
The EMA’s Committee for Medicinal Products for Human Use has given a positive opinion on Sandoz’ biosimilar trastuzumab for breast and gastric cancer.
September 13, 2023
Recipharm will provide analytical and process development capabilities to support toxicology studies, in addition to GLP manufacturing of lipid nanoparticles to capture the active pharmaceutical ingredient, an antigen peptide.
September 11, 2023
The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors.
September 06, 2023
Advanced analytical tools generate more data in today’s labs than ever before.
September 05, 2023
Webinar Date/Time: Wed, Oct 11, 2023 11:00 AM EDT
September 03, 2023
Excipients should be treated equally when it comes to quality management, risk assessment, and testing.
Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.
September 02, 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
August 31, 2023
Extensive research on various gene editing techniques could inform the future of mRNA therapies.